KRAS and cancer: We used publically available data from the cancer cell line encyclopaedia (CCLE) database to search for mutations in EGFR, ERBB2, ERBB3, ERBB4, KRAS and BRAF that might predispose to a different response to anti-HER2 therapies or PI3K or MAPK pathway inhibition.